Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 13Gastrointestinal 9Thoracic 7CNS 6Breast 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Solid Tumors Harboring a BRAF V600 Mutation 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × binimetinib × Other solid neoplasm × Clear all
NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Pfizer

Phase 1/2 Completed
189 enrolled 44 charts
Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡